Artificial intelligence is becoming an increasingly important tool in scientific research, helping scientists analyse complex datasets, generate new hypotheses and speed up discoveries that would otherwise take years. Anthropic is now directing that capability toward one of medicine’s most challenging areas: rare diseases.
The AI company has launched a Rare Disease Research Grant Program, a new initiative under its AI for Science program that will provide eligible researchers with up to $50,000 in Claude API credits over six months. The grants are intended to help scientists studying rare genetic diseases use Anthropic’s AI models to accelerate research and drug discovery. Applications are open until August 2, 2026.
According to Anthropic, this is the first disease-specific funding call under its AI for Science initiative, which was introduced in 2025 to support high-impact scientific research through free access to Claude’s API. Rather than providing cash grants, Anthropic is offering computing resources that researchers can use to analyse biological data, interpret scientific literature, generate research ideas and support other computational tasks.
The program is divided into two tracks. The first is aimed at academic researchers, nonprofit organisations and research institutions working on the biology, genetics and data infrastructure surrounding rare diseases. The second targets early-stage biotechnology companies developing treatments for rare genetic disorders, with an emphasis on projects where AI could meaningfully reduce the time required for drug discovery and development.
Successful applicants will receive up to $50,000 worth of Claude API credits to be used over six months. Participants will also gain access to Anthropic’s AI tools, including Claude models designed to assist with scientific reasoning, literature review, experimental planning and biological data analysis. The company said applications will be evaluated based on scientific merit, the potential impact of the research and whether AI can substantially accelerate the proposed work.
Rare diseases affect hundreds of millions of people globally, yet many conditions remain poorly understood because patient populations are small and research funding is often limited. Anthropic believes advanced AI systems can help researchers overcome some of these challenges by processing large volumes of scientific information more quickly and identifying patterns that might otherwise go unnoticed.
The announcement reflects a broader trend across the AI industry, where companies are increasingly positioning their models as research assistants rather than just productivity tools. Generative AI is already being used in areas such as protein structure prediction, genomics, drug discovery and clinical research, allowing scientists to automate repetitive tasks and spend more time validating new ideas through experiments.
Anthropic’s AI for Science program was launched to support researchers working on projects with the potential for significant scientific impact, particularly in biology and life sciences. The new rare disease grants represent the program’s first targeted research initiative, signalling the company’s intention to expand the use of Claude beyond general-purpose AI into specialised scientific applications.
If successful, the initiative could help researchers make faster progress on diseases that have historically received limited attention while demonstrating how frontier AI models can contribute to scientific discovery. For Anthropic, it also reinforces a growing focus on applying artificial intelligence to real-world challenges with measurable social impact, extending Claude’s role beyond business and software development into biomedical research.
Read also:Bitcoin developers propose plan to counter quantum threats